Establishment of a DBS for the procurement of medicinal products of different indication groups in different dosage forms.

The DBS takes place in 2 phases:

1. Establishment and administration of a pool of bidders

The DBS shall be set up for the specified duration and range of services. The procedure is carried out exclusively electronically. The contracting authority shall form a pool of tenders.

Anyone interested can activate participation in the procedure at any time during the DBS and submit an application to participate. Any interested party who meets the eligibility criteria published in the notice will be included in the bidder pool. He thus becomes a potential bidder and can submit an offer for the subsequent individual awards.

The pool of bidders is not limited in size. Every qualified participant is included in the bidder pool.

2. Offer phase

The specific procurements take place depending on the needs of the public client in the context of the offer phase in the form of individual awards. The client decides on the point in time or the number of individual awards. It is expressly pointed out that there is no obligation on the part of the client to carry out individual awards.

On the occasion of individual award, the contracting authority shall invite all participants in the pool of tenderers admitted to the DBS to submit a tender and shall inform them of the specific terms of the contract (e.g. quantity, delivery time, place of delivery, award criteria, etc.), unless they have already been published in the contract notice.

By submitting an offer, the bidder declares that there will be no changes to the suitability criteria. The offers received will be checked in terms of content and against the announced award criteria. The bidder with the most economical offer to be determined on the basis of the notified award criteria will be awarded the contract.

The participants admitted to the DBS bidder pool are not obliged to submit an offer as part of the individual awards.

The participants must always find out about the current status of the award procedure (the individual award). Any deadline extensions, applicant questions with the corresponding answers or other updates and changes must be accessed independently by the participant on the federal e-procurement platform. Any changes will be announced immediately by the client.

60,000,000 units (units)

It is intended, for example, to contract the following medicines within the framework of the DBS.

The quantities specified (total time = duration of the DBS; demand 2021 = projected annual demand 2021) represent forecast values.

It is expressly pointed out that further active ingredients can be placed through individual awards.

In addition, it is envisaged to prematurely terminate the DBS antibiotics and the DBS antidotes, corticoids, narcotics, analgesics and anticoagulants on 31.12.2021 and transfer them to the DBS in question on 1.1.2022.

Legend: AM = ampoule, EA = piece, TU = tube, BT = bottle, TBL = tablet, IE = international unit

Kardiaka 1st adenosine injection (active ingredient adenosine 6 MG/ 2ML), total requirement approx. 31 010 AM, 2021 needs approximately 30 210 AM,

2. Amlodipine tablet (active ingredient amlodipine 5 mg), total requirement approx. 907 000 EA, 2021 needs approximately 2 400 EA, 3. Cafedrin and theodrenaline hydrochloride injection (active ingredient 1 cafedrin 200 mg, active ingredient 2 theodrenaline 10 mg), total requirement approx. 47.562

4. Candesartan cilexetil tablets (active ingredient candesartan 16 mg divisible) total requirement approx. 1,730,176 EA, 2021 needs approximately 0 EA

5. Long-release metoprolol succinate tablets (active ingredient metoprolol 39.91 mg divisible) total requirement approx. 481,540 EA, 2021 requires approx. 5,100 EA

6. Ramipril tablet (active ingredient RAMIPRIL 2.5 MG), total requirement approx. 804,180 EA, 2021 needs approximately 0 EA

7. Ramipril tablet (active ingredient RAMIPRIL 10MG) total requirement approx. 168,200 EA, 2021 needs approximately 3,600 EA

Antiemetics

1. Dimenhydrinate injection (active ingredient dimenhydrinate 62 mg), total requirement approx. 31,220 AM, 2021 needs approx. 29.040 AM

2. Dimenhydrinate injection (active ingredient dimenhydrinate 100 mg, active ingredient 2 benzyl alcohol 105 mg) total requirement approx. 17,524 AM, 2021 needs approximately 12,000 AM

3. Dimenhydrinate tablets (active ingredient dimenhydrinate 50 mg) total requirement approx. 1,700,000 EA, 2021 needs approximately 1,940 EA

4. Ondansetron hydrochloride injection (active substance ondansetron 4 mg) total requirement approx. 46.485 AM, 2021 needs approximately 12.025 AM

Ophthalmics

1. Acetazolamide tablet (active ingredient acetazolamide 250 mg) total requirement approx. 93,930 EA, 2021 needs approximately 90,130 EA

2. Dexpanthenol ointment (active ingredient dexpanthenol 50 mg) total requirement approx. 157,132 TU, 2021 needs approx. 27,930 TU

3. Sodium chloride solution (active ingredient sodium chloride 4.5 GM) total requirement approx. 19,848 BT, 2021 requires approx. 6,648 BT

4. Oxybuprocaine hydrochloride eye drops (active ingredient oxybuprocaine 4 MG) total requirement approx. 24.513 BT, 2021 requires approx. 19,970 BT

Dermatics

1. Aciclovir cream (active ingredient acyclovir 50 MG/G) total requirement approx. 32,090 TU, 2021 needs approximately 522 TU

2. Dexpanthenol eye and nasal ointment (active ingredient dexpanthenol 50 MG/G) total requirement approx. 157,132 TU, 2021 needs approx. 27,930 TU

3. Fat cream for the treatment of skin diseases on dry skin (active ingredient fatty acids, unsaturated 8.15 mg) total requirement approx. 27.413 TU, 2021 needs approx. 2,040 TU

4. Miconazole nitrate _Fluprednid cream (active ingredient 1 miconazole 1 mg, active ingredient 2 flaprednids 0.9 mg) total requirement approx. 15.023 TU, 2021 needs approx. 4,890 TU

Gastrointestinal Therapeutics 1st loperamide hydrochloride capsule (active ingredient loperamide 1.860 mg) total requirement approx. 851,473 EA, 2021 needs approximately 260,200 EA

2. Magaldrate suspension (active ingredient Magaldrate 1600 MG) total requirement approx. 198,570 BG, 2021 needs approx. 0 BG

3. Pantoprazole sodium tablet (active ingredient pantoprazole sodium 1,5-water 45.110 mg) total requirement approx. 7,512,528 EA, 2021 needs approximately 46,020 EA

4. Simeticon chewable tablets (active ingredient dimeticone 40 mg) total requirement approx. 274,260 EA, 2021 needs approx. 0 EA

Cold 1. Cetylpyridinium chloride and benzocaine lozenge (active ingredient 1 cetylpyridinium 1.4 MG, active ingredient 2 benzocaine 10 mg) total requirement approx. 5,917,888 EA

2. Myrtol capsules (active ingredient MYRTOL 300 mg) total requirement approx. 2,593,640 EA, 2021 needs approximately 48,400 EA

3. Acetylcysteine tablet (active ingredient acetylcysteine 600 mg) total requirement approx. 558.430 EA, 2021 needs approximately 72,680 EA

Broncholytic antiasthmactics 1st codeine phosphate tablet (active ingredient codeine 22.1 mg) total requirement approximately 153,118 EA. Requirement 2021 approx. 50,400 EA

2. Ipratropium bromide solution for a nebulizer (active ingredient ipratropium bromide 0.25 mg) total requirement approx. 47,902 AM, 2021 needs approximately 36.420 AM 3. Salbutamol aerosol (active ingredient salbutamol 1.25 mg) total requirement approx. 178,150 EA

Antimycotics 1st bifonazole cream (active ingredient bifonazole 10 mg) total requirement approx. 10,000 TU, needs 2021 approx. 0 TU

2. Itraconazole capsule (active ingredient itraconazole 100 mg) total requirement approx. 24.080 EA, 2021 needs approximately 1,190 EA

3. Terbinafine hydrochloride cream (active ingredient terbinafine 10 mg) total requirement approx. 10,561 TU, 2021 needs approx. 3,638 TU

Opharyngeal therapeutics 1st chlorhexidine digluconate solution (active ingredient chlorhexidine 1.13 mg) total requirement approx. 23,190 BT, 2021 needs approx. 90 BT

2. Chlorhexidine digluconate gel (active ingredient chlorhexidine digluconate 10 mg) total requirement approx. 1,890 TU, 2021 needs approx. 90 TU

Diurektika 1. Furosemide sodium infusion (active ingredient furosemide 250 MG/25ML) total requirement approx. 4,278 AM, 2021 needs approximately 1,680 AM

2. Furosemide sodium injection (active substance furosemide 20 MG/ 2ML) total requirement approx. 121,870 AM, 2021 needs approximately 53,950 AM

3. Furosemide sodium injection (active ingredient furosemide 40 MG/4ML) total requirement approx. 26,040 AM, requirement 2021 approx. 25,680 AM

4. Hydrochlorothiazide tablets (active ingredient hydrochlorothiazide 12.5 mg) total requirement approx. 480,000 EA, requirement 2021 approx. 0 EA

1. Clonazepam injection total requirement approx. 38,950 AM, requirement 2021 approx. 36,870 AM